Literature DB >> 19750574

Prognostic analysis of patients with pancreatic head adenocarcinoma less than 2 cm undergoing resection.

Kun-Chun Chiang1, Chun-Nan Yeh, Wei-Chen Lee, Yi-Yin Jan, Tsann-Long Hwang.   

Abstract

AIM: To investigate the differences in clinicopathological features between patients with pancreatic cancer greater or less than 2 cm situated over the pancreatic head and the prognostic factors for survival of patients with pancreatic cancer < 2 cm over the pancreatic head.
METHODS: From 1983 to 2006, 159 patients with histologically proven pancreatic adenocarcinoma (PAC) at the pancreatic head undergoing curative resection at the Department of Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan were reviewed, comprising 123 cases of large (L)-PAC (tumor > 2 cm) and 36 cases of small (S)-PAC (tumor </= 2 cm). We compared the clinicopathological characteristics and prognosis of L-PAC and S-PAC patients. The clinicopathological characteristics of S-PAC were investigated to clarify the prognosis predictive factors of S-PAC.
RESULTS: One hundred and fifty-nine PAC patients, aged 16-93 years (median, 59.0 years) with a tumor at the pancreatic head undergoing intentional curative resection were investigated. The S-PAC and L-PAC patients had similar demographic data, clinical features, and tumor markers (a similar positive rate of carcinoembryonic antigen and carbohydrate antigen 19-9). There were also similar rates of lymph node metastasis, portal vein invasion, stage distribution, tumor differentiation, positive resection margin, surgical morbidity and mortality observed between the two groups. During a follow-up period ranging from 1.0 to 122.7 mo (median, 10.9 mo), S-PAC and L-PAC patients had a similar prognosis after resection (P = 0.4805). Among the S-PAC patients group, patients with higher albumin level (> 3.5 g/dL) had more favorable survival than those with lower albumin levels, which was the only favorable predictive prognostic factor. Meanwhile, early-staged (stage I, II) S-PAC patients tended to have a more favorable outcome than late-stage (stage III, IV) S-PAC patients, but this was not statistically significant.
CONCLUSION: S-PAC patients should not be regarded as early PAC. Only higher albumin level (> 3.5 g/dL) and early stage disease (stage I, II) were the favorable prognosis factors for S-PAC patients.

Entities:  

Mesh:

Year:  2009        PMID: 19750574      PMCID: PMC2744187          DOI: 10.3748/wjg.15.4305

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas.

Authors:  K Satake; H Nishiwaki; H Yokomatsu; Y Kawazoe; K Kim; A Haku; K Umeyama; I Miyazaki
Journal:  Surg Gynecol Obstet       Date:  1992-09

2.  Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality.

Authors:  M Trede; G Schwall; H D Saeger
Journal:  Ann Surg       Date:  1990-04       Impact factor: 12.969

3.  The diagnosis of "early" pancreatic cancer: the University of Chicago experience.

Authors:  A R Moossa; B Levin
Journal:  Cancer       Date:  1981-03-15       Impact factor: 6.860

4.  The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers. A retrospective study.

Authors:  K Satake; Y S Chung; K Umeyama; T Takeuchi; Y S Kim
Journal:  Cancer       Date:  1991-07-01       Impact factor: 6.860

Review 5.  The clinical utility of the CA 19-9 tumor-associated antigen.

Authors:  W Steinberg
Journal:  Am J Gastroenterol       Date:  1990-04       Impact factor: 10.864

6.  Clinicopathological aspects of small pancreatic cancer.

Authors:  Shinichi Egawa; Kazunori Takeda; Shoji Fukuyama; Fuyuhiko Motoi; Makoto Sunamura; Seiki Matsuno
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

7.  Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors.

Authors:  Sean P Cleary; Robert Gryfe; Maha Guindi; Paul Greig; Lloyd Smith; Robert Mackenzie; Steven Strasberg; Sherif Hanna; Bryce Taylor; Bernard Langer; Steven Gallinger
Journal:  J Am Coll Surg       Date:  2004-05       Impact factor: 6.113

8.  Small carcinoma of the pancreas. Clinical and pathologic evaluation of 17 patients.

Authors:  T Manabe; T Miyashita; G Ohshio; A Nonaka; T Suzuki; K Endo; M Takahashi; T Tobe
Journal:  Cancer       Date:  1988-07-01       Impact factor: 6.860

9.  Collective review of small carcinomas of the pancreas.

Authors:  R Tsuchiya; T Noda; N Harada; T Miyamoto; T Tomioka; K Yamamoto; T Yamaguchi; K Izawa; T Tsunoda; R Yoshino
Journal:  Ann Surg       Date:  1986-01       Impact factor: 12.969

10.  Clinicopathological aspects of 542 cases of pancreatic cancer: a special emphasis on small pancreatic cancer.

Authors:  Kee Wook Jung; Myung Hwan Kim; Tae Yoon Lee; Seunghyun Kwon; Hyoung Chul Oh; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

View more
  8 in total

Review 1.  Indications for staging laparoscopy in pancreatic cancer.

Authors:  Antonella De Rosa; Iain C Cameron; Dhanwant Gomez
Journal:  HPB (Oxford)       Date:  2015-11-18       Impact factor: 3.647

Review 2.  Pleiotrophin promotes perineural invasion in pancreatic cancer.

Authors:  Jun Yao; Xiu-Feng Hu; Xiao-Shan Feng; She-Gan Gao
Journal:  World J Gastroenterol       Date:  2013-10-21       Impact factor: 5.742

3.  Poor prognosis of common-type invasive ductal carcinomas that originate in the branching pancreatic duct.

Authors:  Masataka Ando; Yasuhiro Shimizu; Tsuyoshi Sano; Yoshiki Senda; Yuji Nimura; Kenji Yamao; Masato Nagino; Akio Yanagisawa
Journal:  Surg Today       Date:  2014-12-05       Impact factor: 2.549

Review 4.  Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting.

Authors:  Nardeen Perko; Shaker A Mousa
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

5.  The advances of Midkine with peripheral invasion in pancreatic cancer.

Authors:  Jun Yao; Wen-Yao Li; She-Gan Gao
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

6.  Impact of tumor size on survival of patients with resected pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.

Authors:  Debang Li; Bin Hu; Yanming Zhou; Tao Wan; Xiaoying Si
Journal:  BMC Cancer       Date:  2018-10-16       Impact factor: 4.430

7.  The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma.

Authors:  Aaron T Wild; Xiaobu Ye; Susannah G Ellsworth; Jessica A Smith; Amol K Narang; Tanu Garg; Jian Campian; Daniel A Laheru; Lei Zheng; Christopher L Wolfgang; Phuoc T Tran; Stuart A Grossman; Joseph M Herman
Journal:  Am J Clin Oncol       Date:  2015-06       Impact factor: 2.339

8.  CT Imaging Biomarkers Predict Clinical Outcomes After Pancreatic Cancer Surgery.

Authors:  Liang Zhu; Xiaohua Shi; Huadan Xue; Huanwen Wu; Ge Chen; Hao Sun; Yonglan He; Zhengyu Jin; Zhiyong Liang; Zhuoli Zhang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.